Squamous Cell Lung Cancer
Showing 1 - 25 of >10,000
Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,
Not yet recruiting
- Advanced Lung Squamous Cell Carcinoma
- low-dose radiation therapy and stereotactic body radiation therapy
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Nov 13, 2023
NSCLC, Squamous Cell Carcinoma Trial in Wuhan (Nab-paclitaxel, Carboplatin, Thoracic radiation therapy)
Terminated
- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma
- Nab-paclitaxel
- +2 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Apr 26, 2022
Advanced Squamous Non Small Cell Lung Cancer Trial (AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel)
Not yet recruiting
- Advanced Squamous Non Small Cell Lung Cancer
- AK112, Carboplatin, Paxlitaxel
- Tislelizumab, Carboplatin, Paxlitaxel
- (no location specified)
Apr 21, 2023
NSCLC, Metastatic Non Small Cell Lung Cancer, Stage IV NSCLC Trial in Duarte, Minneapolis (Fludarabine, Cyclophosphamide, CISH
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- +5 more
- Fludarabine
- +4 more
-
Duarte, California
- +1 more
Dec 7, 2022
Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)
Not yet recruiting
- Advanced Squamous Non-Small-Cell Lung Cancer
- Trilaciclib
- +3 more
- (no location specified)
Jun 11, 2023
Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer Trial in France (pembrolizumab; vorinostat)
Active, not recruiting
- Squamous Cell Lung Cancer
- +5 more
- pembrolizumab; vorinostat
-
Angers, France
- +13 more
Jan 4, 2023
Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)
Not yet recruiting
- Sinonasal Cancer
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 5, 2023
Exhaled Breath Particles in Lung Cancer
Recruiting
- Lung Cancer
- +3 more
- EBPcollected using the PExA device.
-
Lund, Skåne Län, SwedenSkåne University Hospital
May 24, 2022
Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
- Toripalimab plus Chemotherapy
- (no location specified)
Jul 28, 2023
NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Ivonescimab Injection
- Pembrolizumab Injection
- (no location specified)
Jun 9, 2023
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only
Not yet recruiting
- PARP Inhibitor for Esophageal Squamous Cell Carcinoma
- Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
- (no location specified)
Sep 24, 2023
Progression of Invasive Squamous Cell Carcinoma
Recruiting
- Carcinoma, Squamous Cell
- +10 more
- DNA Extraction
-
Rochester, MinnesotaMayo Clinic in Rochester
Sep 27, 2022
Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)
Not yet recruiting
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- HMBD-001
- +2 more
-
Sydney, New South Wales, AustraliaGenesisCare North Shore
Jun 20, 2023
NSCLC Trial in Chongqing (procedure, drug, radiation)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- bronchial artery interventional therapy
- +3 more
-
Chongqing, Chongqing, ChinaDaping Hospital, Third Military Medical University
May 27, 2023
NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)
Recruiting
- Non-small Cell Lung Cancer
- Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
-
Wuhan, Hubei, ChinaUnion hospital
Feb 20, 2023
NSCLC Trial in Pittsburgh (M1774, Cemiplimab)
Not yet recruiting
- Non-Small Cell Lung Cancer
-
Pittsburgh, PennsylvaniaUPMC Cancer Center
May 22, 2023
NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tiragolumab
- +3 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Feb 16, 2023
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC V7 Trial in Houston (ABBV-399)
Completed
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC V7
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2021
Non-Squamous NSCLC (NSCLC), Adenocarcinoma of the Lung, Lung Cancer Trial in United States (Docetaxel, Nivolumab, Gemcitabine)
Terminated
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- +3 more
- Docetaxel
- +3 more
-
Anderson, Indiana
- +8 more
Jul 7, 2022
Subjects Treated With Autologous T Cells Using Sleeping Beauty
Not yet recruiting
- Gynecologic Cancer
- +9 more
- Neoantigen specific TCR-T cell drug product
-
Houston, TexasMD Anderson Cancer Center
Jul 27, 2022